Income Statement
BENITEC BIOPHARMA INC.
BNTC
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Jun 30, 2025 2025 FY | Jun 30, 2024 2024 FY | Jun 30, 2023 2023 FY | Jun 30, 2022 2022 FY | Jun 30, 2021 2021 FY | Jun 30, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | 0.06 | 0.10 |
|
Cost of Revenue
|
- | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | 0.06 | 0.10 |
|
Operating Expenses
|
41.77 | 22.49 | 19.16 | 17.93 | 13.66 | 8.38 |
|
Research & Development
|
18.33 | 15.61 | 12.77 | 11.27 | 7.02 | 3.00 |
|
Selling, General & Administrative
|
23.43 | 6.99 | 6.38 | 6.65 | 6.51 | 5.57 |
|
Other Operating Expenses
|
- | - | - | - | - | - |
|
Operating Income
|
-41.77 | -22.49 | -19.16 | -17.93 | -13.60 | -8.28 |
|
Non-Operating Income
|
3.85 | 0.74 | -0.48 | -0.35 | -0.29 | 0.01 |
|
Interest Income
|
- | - | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
-0.13 | -0.20 | -0.03 | -0.08 | 0.04 | 0.03 |
|
Income Before Tax
|
- | - | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - |
|
Net Income
|
-37.92 | -21.75 | -19.56 | -18.21 | -13.88 | -8.27 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Jun 30, 2025 2025 FY | Jun 30, 2024 2024 FY | Jun 30, 2023 2023 FY | Jun 30, 2022 2022 FY | Jun 30, 2021 2021 FY | Jun 30, 2020 2020 FY |
|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - |
|
EBITDA
|
-41.70 | -22.40 | -19.02 | -17.76 | -13.37 | -8.09 |
|
Earnings Per Share (Basic)
|
-1.05 | -5.51 | -14.12 | -2.23 | - | - |
|
Diluted EPS
|
-1.05 | -5.51 | -14.12 | -2.23 | - | - |
|
Weighted Average Shares
|
36.21 | 4.06 | 1.39 | 8.17 | - | - |
|
Diluted Weighted Avg Shares
|
36.21 | 4.06 | 1.39 | 8.17 | - | - |
|
Comprehensive Income
|
-37.86 | -21.81 | -19.15 | -18.00 | -13.38 | -8.36 |